OGN רווחיות מכירות גולמית Organon Corp

סמל תאגידי ולוגו של Organon & Co. (OGN)

Organon & Co. (OGN) generates revenue through the sale of biosimilars and specialized women's health medications. This gross margin chart demonstrates operational efficiency, where the value of 53.50 serves as the baseline indicator for current profitability. A robust patent portfolio and strict FDA oversight ensure business stability, while future growth is supported by the development of innovative endometriosis treatments and new contraceptives.

רווחיות גולמית: Organon & Co (OGN) עבור 04.07.2022 - 19.11.2026

פילוחים אנליטיים של חברת Organon & Co.

- שווי שוק ותחזית יעד של אנליסטים:
ניתוח מסכם של החברה:Organon (OGN)
מוצרים מיוצרים של Organon & Co

To objectively evaluate Organon & Co. (OGN), investors must analyze production efficiency via the revenue share remaining after covering direct manufacturing costs. The gross margin trend after deducting cost of goods sold reflects the ability of this women's health leader to monetize its portfolio of contraception brands and gynecological innovations, determining the issuer's overall capital stability and profitability potential.